Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Apr;69(4):762–766. doi: 10.1038/bjc.1994.144

Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.

K J O'Byrne 1, J T Ennis 1, P J Freyne 1, L J Clancy 1, J S Prichard 1, D N Carney 1
PMCID: PMC1968808  PMID: 7908220

Abstract

Recent work suggests that between 50 and 75% of small-cell lung cancer (SCLC) tumours have specific high-affinity binding sites for somatostatin. This study evaluated the potential role of the radiolabelled somatostatin analogue, [111In]pentetreotide, in the detection and staging of SCLC in patients prior to and after chemotherapy using scintigraphic imaging techniques. Thirteen patients were studied prior to chemotherapy. Following standard staging six patients had limited stage disease and seven extensive disease. [111In]pentetreotide imaging led to the detection of all primary sites of disease, including a primary site of disease not detectable with chest radiograph or computerised tomography (CT) of the thorax. Five of ten metastatic sites detected by standard staging were also imaged. Furthermore, a cerebellar metastasis was detected in a patient thought to have disease confined to the right hemithorax. This was subsequently confirmed with a CT brain scan. Following chemotherapy [111In]pentetreotide imaging detected residual intrathoracic disease in two of three patients with complete remissions by standard staging and in two patients who had had a partial response to chemotherapy. These results suggest that [111In]pentetreotide imaging may have a role to play in the clinical evaluation of patients with SCLC. Specifically, this technique may be of particular value in detecting residual intrathoracic disease in patients thought to be in complete remission by conventional staging methods.

Full text

PDF
762

Images in this article

763Figure 1
on p.763
763Figure 2
on p.763
764Figure 3
on p.764

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bepler G., Rotsch M., Jaques G., Haeder M., Heymanns J., Hartogh G., Kiefer P., Havemann K. Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects. J Cancer Res Clin Oncol. 1988;114(3):235–244. doi: 10.1007/BF00405828. [DOI] [PubMed] [Google Scholar]
  2. Bogden A. E., Taylor J. E., Moreau J. P., Coy D. H., LePage D. J. Response of human lung tumor xenografts to treatment with a somatostatin analogue (Somatuline). Cancer Res. 1990 Jul 15;50(14):4360–4365. [PubMed] [Google Scholar]
  3. Carney D. N. Biology of small-cell lung cancer. Lancet. 1992 Apr 4;339(8797):843–846. doi: 10.1016/0140-6736(92)90286-c. [DOI] [PubMed] [Google Scholar]
  4. Cuttitta F., Carney D. N., Mulshine J., Moody T. W., Fedorko J., Fischler A., Minna J. D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. 1985 Aug 29-Sep 4Nature. 316(6031):823–826. doi: 10.1038/316823a0. [DOI] [PubMed] [Google Scholar]
  5. Damstrup L., Rygaard K., Spang-Thomsen M., Poulsen H. S. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res. 1992 Jun 1;52(11):3089–3093. [PubMed] [Google Scholar]
  6. Ghirlanda G., Uccioli L., Perri F., Altomonte L., Bertoli A., Manna R., Frati L., Greco A. V. Epidermal growth factor, somatostatin, and psoriasis. Lancet. 1983 Jan 1;1(8314-5):65–65. doi: 10.1016/s0140-6736(83)91594-5. [DOI] [PubMed] [Google Scholar]
  7. Goldenberg D. M. Challenges to the therapy of cancer with monoclonal antibodies. J Natl Cancer Inst. 1991 Jan 16;83(2):78–79. doi: 10.1093/jnci/83.2.78. [DOI] [PubMed] [Google Scholar]
  8. Hansen H. H. Management of small-cell cancer of the lung. Lancet. 1992 Apr 4;339(8797):846–849. doi: 10.1016/0140-6736(92)90287-d. [DOI] [PubMed] [Google Scholar]
  9. Hardy J., Smith I., Cherryman G., Vincent M., Judson I., Perren T., Williams M. The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer. Br J Cancer. 1990 Oct;62(4):684–686. doi: 10.1038/bjc.1990.357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Krenning E. P., Bakker W. H., Breeman W. A., Koper J. W., Kooij P. P., Ausema L., Lameris J. S., Reubi J. C., Lamberts S. W. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989 Feb 4;1(8632):242–244. doi: 10.1016/s0140-6736(89)91258-0. [DOI] [PubMed] [Google Scholar]
  11. Krenning E. P., Bakker W. H., Kooij P. P., Breeman W. A., Oei H. Y., de Jong M., Reubi J. C., Visser T. J., Bruns C., Kwekkeboom D. J. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992 May;33(5):652–658. [PubMed] [Google Scholar]
  12. Krenning E. P., Kwekkeboom D. J., Bakker W. H., Breeman W. A., Kooij P. P., Oei H. Y., van Hagen M., Postema P. T., de Jong M., Reubi J. C. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993 Aug;20(8):716–731. doi: 10.1007/BF00181765. [DOI] [PubMed] [Google Scholar]
  13. Krenning E. P., Kwekkeboom D. J., Reubi J. C., Van Hagen P. M., van Eijck C. H., Oei H. Y., Lamberts S. W. 111In-octreotide scintigraphy in oncology. Metabolism. 1992 Sep;41(9 Suppl 2):83–86. doi: 10.1016/0026-0495(92)90038-c. [DOI] [PubMed] [Google Scholar]
  14. Kwekkeboom D. J., Krenning E. P., Bakker W. H., Oei H. Y., Splinter T. A., Kho G. S., Lamberts S. W. Radioiodinated somatostatin analog scintigraphy in small-cell lung cancer. J Nucl Med. 1991 Oct;32(10):1845–1848. [PubMed] [Google Scholar]
  15. Lamberts S. W., Bakker W. H., Reubi J. C., Krenning E. P. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990 Nov 1;323(18):1246–1249. doi: 10.1056/NEJM199011013231805. [DOI] [PubMed] [Google Scholar]
  16. Lamberts S. W., Hofland L. J., van Koetsveld P. M., Reubi J. C., Bruining H. A., Bakker W. H., Krenning E. P. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab. 1990 Sep;71(3):566–574. doi: 10.1210/jcem-71-3-566. [DOI] [PubMed] [Google Scholar]
  17. Larson S. M. Lymphoma, melanoma, colon cancer: diagnosis and treatment with radiolabeled monoclonal antibodies. The 1986 Eugene P. Pendergrass New Horizons Lecture. Radiology. 1987 Nov;165(2):297–304. doi: 10.1148/radiology.165.2.3498971. [DOI] [PubMed] [Google Scholar]
  18. Macaulay V. M., Carney D. N. Neuropeptide growth factors. Cancer Invest. 1991;9(6):659–673. doi: 10.3109/07357909109039878. [DOI] [PubMed] [Google Scholar]
  19. Macaulay V. M., Everard M. J., Teale J. D., Trott P. A., Van Wyk J. J., Smith I. E., Millar J. L. Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res. 1990 Apr 15;50(8):2511–2517. [PubMed] [Google Scholar]
  20. Macaulay V. M., Smith I. E., Everard M. J., Teale J. D., Reubi J. C., Millar J. L. Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. Br J Cancer. 1991 Sep;64(3):451–456. doi: 10.1038/bjc.1991.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Malec P., Zeman K., Markiewicz K., Tchórzewski H., Nowak Z., Baj Z. Short-term somatostatin infusion affects T lymphocyte responsiveness in humans. Immunopharmacology. 1989 Jan-Feb;17(1):45–49. doi: 10.1016/0162-3109(89)90007-6. [DOI] [PubMed] [Google Scholar]
  22. Mascardo R. N., Sherline P. Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor. Endocrinology. 1982 Oct;111(4):1394–1396. doi: 10.1210/endo-111-4-1394. [DOI] [PubMed] [Google Scholar]
  23. Moody T. W., Carney D. N., Cuttitta F., Quattrocchi K., Minna J. D. High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. Life Sci. 1985 Jul 15;37(2):105–113. doi: 10.1016/0024-3205(85)90413-8. [DOI] [PubMed] [Google Scholar]
  24. Nakamura H., Koike T., Hiruma K., Sato T., Tomioka H., Yoshida S. Identification of lymphoid cell lines bearing receptors for somatostatin. Immunology. 1987 Dec;62(4):655–658. [PMC free article] [PubMed] [Google Scholar]
  25. Reichlin S. Somatostatin (second of two parts). N Engl J Med. 1983 Dec 22;309(25):1556–1563. doi: 10.1056/NEJM198312223092506. [DOI] [PubMed] [Google Scholar]
  26. Reichlin S. Somatostatin. N Engl J Med. 1983 Dec 15;309(24):1495–1501. doi: 10.1056/NEJM198312153092406. [DOI] [PubMed] [Google Scholar]
  27. Reubi J. C., Kvols L., Krenning E., Lamberts S. W. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism. 1990 Sep;39(9 Suppl 2):78–81. doi: 10.1016/0026-0495(90)90217-z. [DOI] [PubMed] [Google Scholar]
  28. Reubi J. C., Waser B., Sheppard M., Macaulay V. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer. 1990 Feb 15;45(2):269–274. doi: 10.1002/ijc.2910450211. [DOI] [PubMed] [Google Scholar]
  29. Sagman U., Mullen J. B., Kovacs K., Kerbel R., Ginsberg R., Reubi J. C. Identification of somatostatin receptors in human small cell lung carcinoma. Cancer. 1990 Nov 15;66(10):2129–2133. doi: 10.1002/1097-0142(19901115)66:10<2129::aid-cncr2820661015>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  30. Sheppard M. N. Neuroendocrine differentiation in lung tumours. Thorax. 1991 Nov;46(11):843–850. doi: 10.1136/thx.46.11.843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sreedharan S. P., Kodama K. T., Peterson K. E., Goetzl E. J. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem. 1989 Jan 15;264(2):949–952. [PubMed] [Google Scholar]
  32. Taylor J. E., Bogden A. E., Moreau J. P., Coy D. H. In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Commun. 1988 May 31;153(1):81–86. doi: 10.1016/s0006-291x(88)81192-6. [DOI] [PubMed] [Google Scholar]
  33. Taylor J. E., Coy D. H., Moreau J. P. High affinity binding of [125I-Tyr11]somatostatin-14 to human small cell lung carcinoma (NCI-H69). Life Sci. 1988;43(5):421–427. doi: 10.1016/0024-3205(88)90521-8. [DOI] [PubMed] [Google Scholar]
  34. Taylor J. E., Moreau J. P., Baptiste L., Moody T. W. Octapeptide analogues of somatostatin inhibit the clonal growth and vasoactive intestinal peptide-stimulated cyclic AMP formation in human small cell lung cancer cells. Peptides. 1991 Jul-Aug;12(4):839–843. doi: 10.1016/0196-9781(91)90143-d. [DOI] [PubMed] [Google Scholar]
  35. Vanhagen P. M., Krenning E. P., Reubi J. C., Mulder A. H., Bakker W. H., Oei H. Y., Löwenberg B., Lamberts S. W. Somatostatin analogue scintigraphy of malignant lymphomas. Br J Haematol. 1993 Jan;83(1):75–79. doi: 10.1111/j.1365-2141.1993.tb04634.x. [DOI] [PubMed] [Google Scholar]
  36. Vehmeyer K., Schuff-Werner P., Nagel G. A. Suppressed colony formation of peripheral blood lymphocytes in a patient with somatostatinoma. Clin Immunol Immunopathol. 1986 Nov;41(2):290–294. doi: 10.1016/0090-1229(86)90113-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES